1. Introduction

Decentralized Genome Doctrine Governance refers to a legal and regulatory framework in which authority over genomic information, genetic research, genome sequencing, genetic databases and genomic technologies is distributed among multiple institutions rather than concentrated in a single government agency or centralized database.

The doctrine seeks to establish a balance between individual genetic privacy, scientific freedom, public health, institutional accountability, data ownership, research collaboration and national sovereignty.

Genome information is particularly sensitive because it can reveal an individual's inherited characteristics, disease susceptibility, ancestry and biological relationships. It may also reveal information about biological relatives who have never consented to genetic testing.

In a decentralized governance model, responsibilities may be distributed among:

National governments and legislative authorities.

Data protection regulators.

Hospitals and medical research institutions.

Universities and genomic research laboratories.

Independent ethics committees.

Genetic testing companies.

Public genomic databases.

International scientific and regulatory organizations.

Important legal clarification: Decentralized Genome Doctrine Governance is an emerging conceptual framework, not a universally recognized, independently codified legal doctrine. Its legal foundations come from constitutional privacy, data protection, bioethics, medical research regulation, intellectual property and administrative accountability.

2. Meaning and Nature of Decentralized Genome Governance

Traditional centralized genome governance places substantial control over genomic information in one institution or national database.

Decentralized governance distributes decision-making authority and operational responsibilities among multiple authorized entities.

For example, a hospital may collect genetic samples, a university may conduct genomic research, a government regulator may supervise research compliance, and an independent ethics committee may review consent requirements.

However, decentralization does not mean that every institution can freely access or commercialize genetic information.

Each institution must operate within legally defined boundaries.

Its central principles include:

Distributed authority: No single institution exercises unlimited control over genomic information.

Individual autonomy: Individuals retain legally protected interests in their genetic information.

Institutional accountability: Each organization remains responsible for its own processing and research activities.

Transparency: Genetic-data collection, sharing and research purposes must be disclosed appropriately.

Scientific collaboration: Authorized institutions can exchange genomic information for legitimate research.

Privacy protection: Genetic information must be protected against unauthorized disclosure and misuse.

3. Legal Foundations of Decentralized Genome Governance

The framework is supported by several areas of law.

A. Constitutional law

Constitutional law protects human dignity, bodily autonomy, informational privacy and personal liberty.

In India, Article 21 of the Constitution is particularly important because genetic information can expose intimate details of a person's identity and biological characteristics.

A decentralized genomic database must therefore operate consistently with constitutional safeguards.

B. Data protection law

Genomic information is personal information when it relates to an identified or identifiable person.

Relevant legal questions include:

Who determines the purpose of genomic-data processing?

Which institution is responsible for protecting the data?

Can genetic information be shared without fresh consent?

Can an individual request correction or erasure?

Who is liable for unauthorized access?

What happens when genomic data is transferred internationally?

C. Bioethics and research regulation

Genomic research requires ethical oversight, informed consent, confidentiality, scientific integrity and protection against discrimination.

The UNESCO International Declaration on Human Genetic Data (2003) provides important international principles concerning consent, confidentiality, withdrawal of consent, cross-border cooperation and benefit-sharing.

Legal Affairs

D. Administrative and institutional law

Decentralized governance requires clear legal boundaries between regulators, laboratories, research institutions and private companies.

Institutions should have defined responsibilities, independent review procedures, audit mechanisms and legally enforceable accountability.

4. Major Doctrinal Principles

4.1 Principle of distributed institutional authority

Under this principle, genomic governance is divided among institutions according to their functions.

For example:

Hospitals control clinical collection and diagnosis.

Universities supervise research projects.

Ethics committees assess research protocols.

Data protection authorities supervise applicable privacy obligations.

Government agencies regulate public-health and forensic uses.

The distribution of authority prevents excessive concentration of sensitive biological information.

However, decentralization must not create regulatory gaps. Every participating institution must have identifiable legal responsibilities.

4.2 Principle of genomic autonomy

Genomic autonomy means that individuals should have meaningful control over the collection, use, disclosure and research application of their genetic information.

Consent should explain:

The purpose of genetic testing.

The institution collecting the information.

Whether information will be shared.

Whether commercial research is contemplated.

Whether future secondary research is permitted.

Whether participants can withdraw consent.

The limitations on withdrawing information already incorporated into completed research.

This principle also raises the question of whether relatives should receive protection when genetic information about one individual reveals information about other family members.

4.3 Principle of institutional accountability

Decentralization cannot be used as a defence against legal responsibility.

If a hospital transfers genomic data to a research institution and the research institution transfers it to a commercial laboratory, each organization must comply with its own legal obligations.

A proper governance framework should establish:

Data-processing agreements.

Access-control policies.

Security standards.

Audit trails.

Breach-reporting procedures.

Independent investigations.

Compensation and remedies where legally available.

4.4 Principle of genomic interoperability

Genomic interoperability refers to the ability of different institutions to exchange and interpret genomic information through compatible technical and legal standards.

For example, a hospital in India may collect genomic information, while an authorized international research institution may analyze the data.

Interoperability should require:

Standardized genomic formats.

Data-quality verification.

Secure transfer mechanisms.

Consistent consent documentation.

Purpose limitations.

Cross-border privacy safeguards.

Technical compatibility alone does not create legal permission to share genetic information.

4.5 Principle of genomic sovereignty

Genomic sovereignty concerns the authority of states, individuals and communities over the collection, storage, access and use of genetic resources and genomic information.

This becomes particularly important when genetic information is collected from Indigenous communities or populations with distinctive ancestry.

Governance should address:

Community participation.

Protection against exploitation.

Fair distribution of research benefits.

Restrictions on unauthorized commercialization.

Respect for cultural and collective interests.

4.6 Principle of decentralized security

A decentralized system can reduce the risks associated with maintaining one enormous genomic database.

For example, a federated research network can allow researchers to conduct approved queries across multiple institutional databases without routinely transferring complete genomic datasets.

Nevertheless, decentralization is not automatically secure. Multiple databases may create additional cybersecurity vulnerabilities, inconsistent access controls and difficulties in identifying responsibility for breaches.

5. Important Case Laws

There is no reported judgment establishing a standalone doctrine called Decentralized Genome Doctrine Governance. However, several important decisions establish principles that can be applied to this emerging framework.

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

India – Supreme Court

Citation: (2017) 10 SCC 1.

Facts and legal issue:

The case concerned whether the Indian Constitution recognizes privacy as a fundamental right. The dispute arose in the context of the Aadhaar identification system and the collection and use of personal information.

Judgment:

The nine-judge Constitution Bench unanimously recognized privacy as a fundamental right under Article 21 and other freedoms guaranteed by Part III of the Constitution.

The Court emphasized informational privacy, individual autonomy, dignity and protection against unjustified interference by state and non-state actors.

Relevance to decentralized genome governance:

The judgment provides a constitutional foundation for protecting genomic information.

If hospitals, laboratories or research institutions collect and share genetic information, their activities must respect constitutional privacy principles and applicable statutory requirements.

The judgment also supports the need for a robust data-protection framework.

Indian Kanoon+1

Case 2: S. and Marper v. United Kingdom (2008)

European Court of Human Rights

Citation: Applications Nos. 30562/04 and 30566/04, Judgment of 4 December 2008.

Facts:

The applicants challenged the retention of their fingerprints, cellular samples and DNA profiles after criminal proceedings against them had ended without conviction.

Judgment:

The European Court of Human Rights held that retaining their DNA material and profiles constituted interference with their right to private life under Article 8 of the European Convention on Human Rights.

The Court emphasized that cellular samples contain extensive genetic information, including information about relatives, and that indefinite retention without sufficient justification was disproportionate.

Relevance:

This case establishes that genetic samples and DNA profiles require strong legal safeguards.

For decentralized genome governance, it supports:

Purpose limitation.

Retention restrictions.

Deletion safeguards.

Protection against unauthorized access.

Proportionality in government databases.

Bailii+1

Case 3: Maryland v. King (2013)

United States – Supreme Court

Citation: 569 U.S. 435 (2013).

Facts:

The case concerned the collection of DNA samples from individuals arrested for serious offences under Maryland law.

Judgment:

The US Supreme Court upheld the DNA collection procedure in the circumstances of the case, treating it as a reasonable identification measure under the Fourth Amendment.

The Court considered the limited identification purpose of the CODIS markers and the statutory safeguards governing their use.

Relevance:

This judgment demonstrates that genomic governance involves balancing public interests against individual privacy.

For decentralized systems, it highlights the importance of defining:

Permitted DNA-testing purposes.

Access to forensic databases.

Restrictions on secondary use.

Statutory safeguards.

Limits on the information extracted from samples.

The decision should not be understood as general authorization for unrestricted genetic surveillance.

LII / Legal Information Institute

Case 4: Selvi v. State of Karnataka (2010)

India – Supreme Court

Citation: (2010) 7 SCC 263.

Facts:

The case concerned the involuntary administration of scientific investigative techniques, including narcoanalysis, polygraph examinations and Brain Electrical Activation Profile tests.

Judgment:

The Supreme Court held that involuntary administration of these techniques violated constitutional protections under Articles 20(3) and 21 in the circumstances considered.

Relevance:

Although the judgment did not concern genome sequencing, its principles concerning bodily integrity, mental privacy and personal autonomy are relevant to involuntary genetic testing.

It supports the proposition that scientific progress cannot automatically override fundamental individual rights.

Indian Kanoon

6. Indian Legal Framework

India does not presently have a single comprehensive statute exclusively governing all aspects of genomic information. Instead, genomic governance operates through constitutional principles, data-protection legislation, biomedical research rules and sector-specific regulations.

A. Constitution of India

The most relevant provisions are:

Article 14: Protection against arbitrary and discriminatory state action.

Article 19: Protection of applicable freedoms, including expression and scientific activity subject to constitutional restrictions.

Article 21: Protection of life, personal liberty, dignity and privacy.

Article 20(3): Protection against compelled self-incrimination.

These provisions can become relevant when genomic information is collected for healthcare, research, identification or criminal investigation.

B. Digital Personal Data Protection Act, 2023

The DPDP Act establishes a statutory framework for processing digital personal data in India.

Its relevance to genomic governance includes:

Processing personal data for lawful purposes.

Consent and specified legitimate uses under the Act.

Security safeguards.

Obligations of data fiduciaries.

Rights of data principals.

Regulatory oversight and penalties.

Genetic information is not separately classified as a distinct category in the Act's basic definition of personal data. Nevertheless, genomic information that identifies or relates to an individual can fall within its scope.

The research-related exemption under Section 17(2)(b) is also important, subject to the prescribed conditions and standards.

C. National Ethical Guidelines for Biomedical and Health Research

The Indian Council of Medical Research (ICMR) guidelines provide ethical standards for biomedical research involving human participants.

Their significance includes:

Informed consent.

Confidentiality.

Protection of vulnerable participants.

Independent ethics committee review.

Responsible handling of biological samples.

Ethical use of stored biological materials.

D. Biological Diversity Act, 2002

The Biological Diversity Act may become relevant where genomic research involves biological resources and associated traditional knowledge within its statutory scope.

Issues can include access regulation, benefit-sharing and protection against unauthorized exploitation.

However, human genomic information should not automatically be treated as equivalent to biological resources governed by this legislation.

E. Research institutions and ethics committees

Hospitals, universities and genomic laboratories must develop institutional governance arrangements consistent with applicable legislation and research standards.

A decentralized system should ensure that ethical approval at one institution does not automatically authorize every subsequent use of the data by another institution.

7. Major Legal Challenges

7.1 Fragmentation of regulatory authority

One of the biggest challenges is the distribution of responsibility among different authorities.

A hospital may follow medical regulations, a research university may follow ethics guidelines, and a private genomic company may operate under data-protection requirements.

When responsibilities overlap, uncertainty can arise concerning which institution is responsible for unlawful processing.

Legal solution: Establish clear statutory responsibility, institutional agreements and coordinated regulatory supervision.

7.2 Genetic discrimination

Genetic information may be misused by employers, insurance companies, financial institutions or other organizations.

For example, an employer might attempt to exclude an applicant because of a genetic predisposition to a particular disease.

Legal solution: Introduce clear restrictions against discriminatory use of genetic information and effective remedies for affected individuals.

7.3 Cross-border genomic-data sharing

International genomic research often requires the transfer of genetic information between institutions located in different countries.

This raises questions concerning:

Different privacy standards.

Foreign government access.

International research agreements.

Consent requirements.

Data localization.

Commercial exploitation.

UNESCO's International Declaration on Human Genetic Data specifically addresses international cooperation and the need for adequate protection when genetic information crosses national borders.

Legal Affairs

7.4 Commercial ownership disputes

Genomic information may generate significant commercial value through pharmaceutical research, diagnostics, artificial intelligence and biotechnology.

Legal disputes may arise concerning:

Who controls stored genetic samples?

Who may commercialize research findings?

Whether participants are entitled to benefit-sharing.

Whether genomic databases can be licensed.

Whether researchers can patent inventions developed through genomic research.

A distinction must be maintained between ownership of a biological sample, control over personal data and intellectual property rights in a resulting invention.

7.5 Cybersecurity and decentralized databases

Distributed databases may be vulnerable to unauthorized access, ransomware, data manipulation and identity re-identification.

Even apparently anonymized genomic datasets may create privacy risks because genetic information can be connected with other databases.

Legal solution: Require encryption, authentication, access logging, independent security audits, breach response procedures and strict restrictions on re-identification.

7.6 Consent and intergenerational privacy

Genetic information is not purely individual information. It can reveal biological relationships and inherited risks affecting relatives and future generations.

Consequently, traditional individual consent models may not resolve every ethical question.

A governance framework must balance individual autonomy, family interests, community concerns and legitimate public-health objectives.

8. Recommended Model of Decentralized Genome Governance

A legally effective decentralized framework should combine distributed institutional administration with centralized minimum legal standards.

Proposed governance architecture

National constitutional and statutory framework

Privacy, dignity, autonomy and minimum legal standards

Healthcare institutions

Clinical genomic data

Research institutions

Scientific research

Ethics committees

Consent and oversight

Data regulators

Privacy and compliance

Secure genomic-data sharing network

Federated access, interoperability and controlled research collaboration

Individual and community protection

Privacy, transparency, remedies and fair benefit-sharing

The proposed architecture has five essential components:

A common national legal framework.

Independent institutional decision-making.

Secure decentralized genomic databases.

Coordinated regulatory supervision.

Accessible legal remedies for individuals and affected communities.

This model allows scientific institutions to retain operational independence without sacrificing legal accountability.

9. International Governance and Regulatory Cooperation

Decentralized genomic governance requires international cooperation because genetic information is frequently exchanged across national borders.

Important international instruments include:

The UNESCO Declaration is particularly relevant because it recognizes the need for independent, multidisciplinary, pluralistic and transparent monitoring arrangements for genetic-data governance.

Legal Affairs

10. Liability and Remedies

A decentralized governance system must provide effective remedies when an institution violates genomic rights.

Potential legal consequences include:

1. Civil liability: Compensation or other remedies where unauthorized disclosure or misuse causes legally recognizable harm.

2. Regulatory liability: Penalties for violations of applicable data-protection requirements.

3. Constitutional remedies: Judicial review of unlawful state interference with genetic privacy and personal liberty.

4. Contractual liability: Breach of research agreements, confidentiality obligations or data-processing agreements.

5. Institutional liability: Disciplinary and administrative consequences for research misconduct or failure to follow applicable ethical requirements.

6. Criminal liability: Where the conduct independently satisfies the elements of an applicable criminal offence.

A particularly important question is whether a parent institution can avoid responsibility by claiming that the actual misuse was committed by an independent research partner. Decentralization should not eliminate accountability where the law imposes responsibility on that institution.

11. Future Developments

The doctrine is likely to become increasingly important with the development of:

Artificial intelligence-based genome interpretation.

Federated genomic research networks.

Blockchain-based genomic consent systems.

International DNA databases.

Population-wide genomic sequencing.

Precision medicine.

Commercial genomic ancestry platforms.

Gene-editing technologies.

Predictive genetic healthcare.

Community-controlled genomic repositories.

Future regulation will need to distinguish between decentralized storage, decentralized decision-making and decentralized legal responsibility.

For example, blockchain may help maintain records of consent and access, but it cannot independently establish that a particular genetic-data disclosure was lawful.

Similarly, federated learning may reduce the need to transfer raw genomic information, but it does not eliminate all privacy risks.

12. Critical Legal Analysis

The most important doctrinal tension is between decentralization and accountability.

Decentralization encourages innovation because universities, hospitals, laboratories and biotechnology companies can collaborate without relying entirely on one centralized authority.

However, it can also create regulatory fragmentation.

Three major questions arise:

First: Who controls genomic information?

The answer cannot simply be that the institution storing the information has unlimited control over it. Individual privacy, consent, statutory rights and research obligations must remain protected.

Second: Who is responsible for misuse?

Responsibility should be allocated according to the actual legal role of each institution, its decisions and its processing activities.

Third: How can scientific collaboration coexist with privacy?

The solution requires purpose limitation, proportionate access, secure infrastructure, transparent agreements and independent oversight.

The strongest approach is therefore a hybrid governance model: decentralized institutional operations under common constitutional and statutory safeguards.

13. Conclusion

Decentralized Genome Doctrine Governance represents an important emerging approach to the regulation of genetic information and genomic research.

Its central objective is to distribute institutional authority while preserving individual autonomy, genetic privacy, scientific accountability and public interest.

The judgments in Puttaswamy, S. and Marper, Maryland v. King and Selvi provide important legal foundations for examining privacy, bodily autonomy, DNA collection and scientific investigation.

In India, constitutional privacy principles, the DPDP Act 2023 and ICMR ethical guidelines provide significant foundations for this developing framework. The DPDP Act's substantive provisions have a phased commencement schedule under the November 2025 notification, so their operative status must be considered when evaluating a particular activity.

MeitY+2

Ultimately, the doctrine supports a system in which genomic research is distributed, scientific cooperation is encouraged, and no institution receives unlimited authority over human genetic information.

14. Important Legal References

Constitution of India, Articles 14, 19, 20(3) and 21.

Digital Personal Data Protection Act, 2023.

National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, ICMR, 2017.

UNESCO International Declaration on Human Genetic Data, 2003.

UNESCO Universal Declaration on the Human Genome and Human Rights, 1997.

Regulation (EU) 2016/679 (GDPR).

Justice K.S. Puttaswamy v. Union of India (2017) 10 SCC 1.

S. and Marper v. United Kingdom (2008), Applications Nos. 30562/04 and 30566/04.

Maryland v. King, 569 U.S. 435 (2013).

Selvi v. State of Karnataka (2010) 7 SCC 263.

Research significance: This topic is especially suitable for advanced biotechnology law research under the combined themes of genomic privacy, decentralized institutional accountability, constitutional governance, genetic-data sovereignty and international bioethics.